PTAB Says Not Unfair To Review Amgen Chemo Patents
The Patent Trial and Appeal Board has agreed to review two patents covering Amgen Inc.'s blockbuster chemotherapy drug Neupogen, rejecting Amgen's argument that its validity contentions in a parallel district court...To view the full article, register now.
Already a subscriber? Click here to view full article